Topic

Articles

Findings from a Tufts study examining the effects of COVID-19 on clinical trials.

COVID-19 and Its Impact on the Future of Clinical Trial Execution

Recognizing pre-pandemic pain points, such as patient engagement and protocol development, could lead to post-pandemic trial success. 

Addressing the Needs of Clinical Trial Sites in a Post-COVID-19 World

Evaluating the lessons learned about trial sites from COVID-19 to form new strategies and improve patient safety for the future.

Shifting Perspectives on Site Networks to Create Positive Change

It's almost impossible to map out study budgets with absolute precision. Planning for the unexpected costs, such as those associated with slow enrollment, protocol amendments, and other contingencies—is vital.

Key Cost Drivers in Clinical Research: Guide to Successful Budgeting

To optimize the Sponsor/CRO relationship, the final proposal must represent a win for both parties.

Clear Scope of Work Specifications Makes for Strong CRO/Sponsor Partnerships

A discussion of the impact of a strategic alliance in to facilitate operational success at the clinical trial site level in Malaysia. 

The ICR-CRM-IQVIA Research Network Collaboration Experience

Sudarshan Hebbar, CMO of CalciMedica, reveals how the FDA, ethics committees, and safety consortia have responded to helping to advance the application of novel therapeutics towards COVID.

A Journey: Biotech, FDA, and Safety Committee Responses to COVID 

Industry experts share their thoughts on the evolution of the functional service provider model, as demand for flexible resourcing grows.

The Rise of FSP Outsourcing in Drug Development

Stakes are high for emerging biopharmaceutical companies to get their relationships with CRO partners right from the outset.

Small Biopharma and CROs: Seeking Stronger Synergies

Biometric functional services, more than any other, can have a significant impact through the standardization of data collection and management.  

How Does FSP Models Complement eSource Implementation?

Creative approaches are needed to address the clinical research workforce “talent wars”

A Competency-Based Approach to Combating the Talent Wars in BioPharma

Clinical Trials Salary and Satisfaction Survey, January 2020

The Institute for Safe Medication Practices has released a new study which breaks down the estimated costs associated with the approval of new pharmaceutical treatments.

New Research Emerges to Challenge Steep Costs of Clinical Trials

Excerpts resulting from the extended discussion on CRO oversight at the recent CBI Finance and Accounting for Bioscience Companies conference.

CRO Oversight Roundtable

In this interview, Linda Rawlings, VP of Neurodegenerative Development at Synteract, elaborates on addressing the challenges of neurodegenerative disease clinical trials.

CROs Tackle Neurodegenerative Disease Studies

Joe Pollarine, Head of GxP Systems Strategy Director at Janssen, recently spoke about CRO oversight models and will expand on these models in this interview.

Janssen Advances Efficiency and Effectiveness in CRO Oversight Model

As the size, complexity, duration, cost, and globalization of clinical trials has grown, pharmaceutical and biotech companies have moved to outsource clinical activities to CROs to achieve a wide range of objectives.

The Emergence of the Few: M&A in the CRO Industry

There are key cultural differences to be aware of before conducting clinical trials in Japan.

Know Before You Go: Japan Trials

Michael Christel is Pharmaceutical Executive and Applied Clinical Trials' Managing Editor. He can be reached at mchristel@mmhgroup.com.

Proposed partnership model explores the value of establishing alliances between CROs and networks of small and emerging biopharma companies.

Think Big on Outsourcing: A Network Approach for Small Biopharma

Exploring sourcing model options for appropriate incorporation of DMCs into a clinical program.